Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction
Open accessThe DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Abstract
Monoamine-based treatments for depression have evolved greatly over the past several years, but shortcomings such as suboptimal efficacy, treatment lag, and residual cognitive dysfunction are still significant. Preclinical and clinical studies using compounds directly targeting glutamatergic neurotransmission present new opportunities for antidepressant treatment, with ketamine having a surprisingly rapid and sustained antidepressant effect that is presumably mediated through glutamate-dependent mechanisms. While direct modulation of glutamate transmission for antidepressant and cognition-enhancing actions may be hampered by nonspecific effects, indirect modulation through the serotonin (5-HT) system may be a viable alternative approach. Based on localization and function, 5-HT can modulate glutamate neurotransmission at least through the 5-HT 1A, 5-HT 1B, 5-HT 3, and 5-HT 7 receptors, which presents a rational pharmacological opportunity for modulating glutamatergic transmission without the direct use of glutamatergic compounds. Combining one or more of these glutamate-modulating 5-HT targets with 5-HT transporter inhibition may offer new therapeutic opportunities. The multimodal compounds vortioxetine and vilazodone are examples of this approach with diverse mechanisms, and their different clinical effects will provide valuable insights into serotonergic modulation of glutamate transmission for the potential treatment of depression and associated cognitive dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vortioxetine has been shown to improve a range of cognitive impairments in depressed patients (McIntyre et al 2014, Pehrson & Sanchez 2014, Sanchez et al 2015).”
From Prefrontal cortex executive processes affected by stress in health and disease (2018) · cites this paper as Pehrson & Sanchez 2014
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Its blockage of the 5-HT3 receptors would improve the glutamatergic and serotoninergic transmission and also the firing of pyramidal neurons in prefrontal cortex, which plays a key role in the cognitive improvement.43”
From A Randomized Controlled Study of Efficacy and Cognitive Function Improvement of Vortioxetine and Escitalopram in Patients with Depression in Chinese Han Nationality (2024) · cites this paper as [43]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Evidence from recent preclinical cognitive behavioral models suggests vortioxetine has a beneficial effect on cognition (Pehrson et al, 2014; Sanchez et al, 2015).”
From A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder (2015) · cites this paper as Pehrson et al, 2014
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, it has been postulated that vortioxetine may improve the cognitive symptoms of MDD through its effects on cognate serotoninergic receptors, which may modulate glutamatergic neurotransmission [90].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“In support of a role for AMPA receptors in treating depression, preclinical studies suggest that ketamine exerts its antidepressant-like effect through AMPA receptors,(39) and that fast action is accompanied by rapid neuronal and synaptic adaptation.(32,40) It is widely believed that neuroadaptive changes represent a…”
Cognitive vulnerability to emotional disorders
Mathews, A., & MacLeod, C. (2005) · Annual Review of Clinical Psychology · doi:10.1146/annurev.clinpsy.1.102803.143916 · Cited by 2,100 · cited 1×
“4,5 Moreover, some cognitive disturbances may predict the development of mood disorders, 6 and furthermore may persist beyond remission.”
Glutamate neurotoxicity in cortical cell culture
Choi, D., Maulucci-Gedde, M., & Kriegstein, A. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-02-00357.1987 · Cited by 1,384
Cognitive deficits in depression: Possible implications for functional neuropathology
Austin, M.-P., Mitchell, P., & Goodwin, G. M. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.200 · Cited by 1,154 · cited 1×
“attention, executive function, and speed of processing.(4,5) Moreover, some cognitive disturbances may predict the development of mood disorders,(6) and furthermore may persist beyond remission.”
Maeng, S., Zarate, C. A., Du, J., Schloesser, R. J., McCammon, J., Chen, G., & Manji, H. K. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.05.028 · Cited by 1,103
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Glutamate receptor function in learning and memory
Riedel, G. (2003) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00272-3 · Cited by 962
Electrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonists
Sprouse, J. S., & Aghajanian, G. K. (1987) · Synapse · doi:10.1002/syn.890010103 · Cited by 845
Lüscher, C., Jan, L. Y., Stoffel, M., Malenka, R. C., & Nicoll, R. A. (1997) · Neuron · doi:10.1016/s0896-6273(00)80381-5 · Cited by 758
A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder
Lee, R. S. C., Hermens, D. F., Porter, M. A., & Redoblado-Hodge, M. A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.10.023 · Cited by 737
Increased Levels of Glutamate in Brains from Patients with Mood Disorders
Hashimoto, K., Sawa, A., & Iyo, M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.017 · Cited by 609
Bang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606
Alterations in 5-HT 1B Receptor Function by p11 in Depression-Like States
Svenningsson, P., Chergui, K., Rachleff, I., Flajolet, M., Zhang, X., Yacoubi, M. E., Vaugeois, J.-M., Nomikos, G. G., & Greengard, P. (2006) · Science · doi:10.1126/science.1117571 · Cited by 572 · cited 1×
“The 5-HT1B receptor has been implicated in the pathophysiology and treatment of depression.(89,90) It has been shown that the 5-HT1B receptor agonist CP-94253 can modulate 5-HT synthesis in the Flinders Sensitive Line rat, an animal model of depression.”
Nelson, J. C., & Papakostas, G. I. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.09030312 · Cited by 552
Preskorn, S. H., Baker, B., Kolluri, S., Menniti, F. S., Krams, M., & Landen, J. W. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818a6cea · Cited by 518
Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood Disorders
Yüksel, C., & Öngür, D. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.016 · Cited by 493
Santana, N. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh070 · Cited by 486 · cited 1×
“As postsynaptic heteroreceptors, 5-HT1A is localized in the hippocampus, septum, amygdala, and corticolimbic areas.(67,68) Based on immunocytochemical studies, the 5-HT1A receptor is expressed in both pyramidal cells and GABAergic interneurons in the cortex and hippocampus.”
Katona, C., Hansen, T., & Olsen, C. K. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283542457 · Cited by 445
Beneyto, M., Kristiansen, L. V., Oni-Orisan, A., McCullumsmith, R. E., & Meador-Woodruff, J. H. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301312 · Cited by 408
Cognitive impairment in the remitted state of unipolar depressive disorder: A systematic review
Hasselbalch, B. J., Knorr, U., & Kessing, L. V. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.11.011 · Cited by 406 · cited 1×
“Moreover, some cognitive disturbances may predict the development of mood disorders,(6) and furthermore may persist beyond remission.(7) Since cognitive dysfunction in depression contributes significantly to disability in some patients,(8) its alleviation is an important goal.”
A Double-Blind, Placebo-Controlled Study of Memantine in the Treatment of Major Depression
Zarate, C. A., Singh, J. B., Quiroz, J. A., De Jesus, G., Denicoff, K. K., Luckenbaugh, D. A., Manji, H. K., & Charney, D. S. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.153 · Cited by 387
Glutamate-based antidepressants: 20 years on
Skolnick, P., Popik, P., & Trullas, R. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.09.002 · Cited by 380
Morales, M., & Bloom, F. E. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-09-03157.1997 · Cited by 361
Functional, molecular and pharmacological advances in 5-HT receptor research
HEDLUND, P., & SUTCLIFFE, J. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.07.002 · Cited by 350
Serotonin receptors: from protein to physiological function and behavior
SARI, Y. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2004.08.008 · Cited by 332
An Open-Label Trial of Riluzole in Patients With Treatment-Resistant Major Depression
Zarate, C. A., Payne, J. L., Quiroz, J., Sporn, J., Denicoff, K. K., Luckenbaugh, D., Charney, D. S., & Manji, H. K. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.171 · Cited by 324
Serotonin receptors involved in antidepressant effects
Artigas, F. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.006 · Cited by 311
Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats
Mørk, A., Montezinho, L. P., Miller, S., Trippodi-Murphy, C., Plath, N., Li, Y., Gulinello, M., & Sanchez, C. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.01.019 · Cited by 298
Involvement of the Anterior Cingulate Cortex in the Expression of Remote Spatial Memory
Teixeira, C. M., Pomedli, S. R., Maei, H. R., Kee, N., & Frankland, P. W. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1068-06.2006 · Cited by 284
Burgdorf, J., Zhang, X.-L., Nicholson, K. L., Balster, R. L., David Leander, J., Stanton, P. K., Gross, A. L., Kroes, R. A., & Moskal, J. R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.246 · Cited by 284
Blier, P. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00036-6 · Cited by 282
Tripp, A., Oh, H., Guilloux, J.-P., Martinowich, K., Lewis, D. A., & Sibille, E. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12020248 · Cited by 273 · cited 1×
“In support of a role for AMPA receptors in treating depression, preclinical studies suggest that ketamine exerts its antidepressant-like effect through AMPA receptors,(39) and that fast action is accompanied by rapid neuronal and synaptic adaptation.(32,40) It is widely believed that neuroadaptive changes represent a…”
Serotonergic Drugs for Depression and Beyond
M. Stahl, S., Lee-Zimmerman, C., Cartwright, S., & Ann Morrissette, D. (2013) · Current Drug Targets · doi:10.2174/1389450111314050007 · Cited by 272
Mørk, A., Pehrson, A., Brennum, L. T., Nielsen, S. M., Zhong, H., Lassen, A. B., Miller, S., Westrich, L., Boyle, N. J., Sánchez, C., et al. (2012) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.189068 · Cited by 271 · cited 2×
“110 5-HT 3 receptor antagonists also augment the effects of SSRIs.”
Self-citationThe serotonin transporter: a primary target for antidepressant drugs
Schloss, P., & Williams, D. C. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200201 · Cited by 265
Beneyto, M., & Meador-Woodruff, J. H. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301604 · Cited by 259
Effect of a single dose of citalopram on amygdala response to emotional faces
Murphy, S. E., Norbury, R., O'Sullivan, U., Cowen, P. J., & Harmer, C. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.056093 · Cited by 255 · cited 1×
“It is widely believed that neuroadaptive changes represent a key event during antidepressant treatment, and may play a role in the delayed onset of efficacy in traditional antidepressants.(41,42) Thus, ketamine’s rapid effects on neuroadaptation may be a key mechanism in its antidepressant effects, and may converge wi…”
Chaki, S., Yoshikawa, R., Hirota, S., Shimazaki, T., Maeda, M., Kawashima, N., Yoshimizu, T., Yasuhara, A., Sakagami, K., Okuyama, S., et al. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2003.10.009 · Cited by 254
Homayoun, H., Stefani, M. R., Adams, B. W., Tamagan, G. D., & Moghaddam, B. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300417 · Cited by 252
Plasma and platelet excitatory amino acids in psychiatric disorders
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.11.1731 · Cited by 243
Anticevic, A., Gancsos, M., Murray, J. D., Repovs, G., Driesen, N. R., Ennis, D. J., Niciu, M. J., Morgan, P. T., Surti, T. S., Bloch, M. H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208494109 · Cited by 243 · cited 1×
“Part of the mechanism for the antidepressant effect of ketamine may involve disinhibition of pyramidal cell firing as a result of the antagonism of NMDA receptors located on interneurons.(38) However, it remains 122 A.”
Increased cerebrospinal fluid glutamine levels in depressed patients
Levine, J., Panchalingam, K., Rapoport, A., Gershon, S., McClure, R. J., & Pettegrew, J. W. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00284-x · Cited by 240
The 5-HT7 receptor and disorders of the nervous system: an overview
Hedlund, P. B. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1626-0 · Cited by 239 · cited 1×
“Therefore, the results from preclinical studies suggest that 5-HT7 receptor antagonism might be a novel strategy for treating depression.(121,122) Additionally, memory-enhancing effects of 5-HT7 antagonists have been shown in preclinical models and have been reviewed elsewhere.”
Thompson, A., & R. Lummis, S. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206778522029 · Cited by 230
Kennett, G. A., Dourish, C. T., & Curzon, G. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90357-8 · Cited by 228
Alvarez, E., Perez, V., Dragheim, M., Loft, H., & Artigas, F. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001027 · Cited by 225 · cited 1×
“–138 Further, in clinical studies, its efficacy as an antidepressant has been demonstrated in several studies to date, 139–145 although statistically significant separation from placebo has not been observed in every clinical trial.”
Antidepressant-like actions of an AMPA receptor potentiator (LY392098)
Li, X., Tizzano, J. P., Griffey, K., Clay, M., Lindstrom, T., & Skolnick, P. (2001) · Neuropharmacology · doi:10.1016/s0028-3908(00)00194-5 · Cited by 225
Novel Drugs and Therapeutic Targets for Severe Mood Disorders
Mathew, S. J., Manji, H. K., & Charney, D. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301652 · Cited by 223
AMPA Receptor Potentiators for the Treatment of CNS Disorders
O'Neill, M., Bleakman, D., Zimmerman, D., & Nisenbaum, E. (2004) · Current Drug Target -CNS & Neurological Disorders · doi:10.2174/1568007043337508 · Cited by 223
Staubli, U., & Xu, F. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-03-02445.1995 · Cited by 217
El Mansari, M., Sánchez, C., Chouvet, G., Renaud, B., & Haddjeri, N. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300686 · Cited by 197
Increased serum glutamate in depressed patients
Kim, J. S., Schmid-Burgk, W., Claus, D., & Kornhuber, H. H. (1982) · Archiv f�r Psychiatrie und Nervenkrankheiten · doi:10.1007/bf00345492 · Cited by 189
Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia
Moghaddam, B. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1792-z · Cited by 189
BELOZERTSEVA, I., KOS, T., POPIK, P., DANYSZ, W., & BESPALOV, A. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.03.002 · Cited by 188
Aznar, S., Qian, Z., Shah, R., Rahbek, B., & Knudsen, G. M. (2003) · Brain Research · doi:10.1016/s0006-8993(02)03727-7 · Cited by 180
Cai, X., Kallarackal, A. J., Kvarta, M. D., Goluskin, S., Gaylor, K., Bailey, A. M., Lee, H.-K., Huganir, R. L., & Thompson, S. M. (2013) · Nature Neuroscience · doi:10.1038/nn.3355 · Cited by 180
Maes, M., Verkerk, R., Vandoolaeghe, E., Lin, A., & Scharpé, S. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb10004.x · Cited by 179
Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism
Gigliucci, V., O’Dowd, G., Casey, S., Egan, D., Gibney, S., & Harkin, A. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3024-x · Cited by 177
ROBINSON, D. S., RICKELS, K., FEIGHNER, J., FABRE, L. F., GAMMANS, R. E., SHROTRIYA, R. C., ALMS, D. R., ANDARY, J. J., & MESSINA, M. E. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199006001-00013 · Cited by 173
The role of glutamate on the action of antidepressants
Hashimoto, K. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.06.013 · Cited by 173
Bonaventure, P., Kelly, L., Aluisio, L., Shelton, J., Lord, B., Galici, R., Miller, K., Atack, J., Lovenberg, T. W., & Dugovic, C. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.119404 · Cited by 169
Translating Glutamate: From Pathophysiology to Treatment
Javitt, D. C., Schoepp, D., Kalivas, P. W., Volkow, N. D., Zarate, C., Merchant, K., Bear, M. F., Umbricht, D., Hajos, M., Potter, W. Z., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002804 · Cited by 168 · cited 1×
“The metabotropic family consists of Group I receptors (mGluR1 and mGluR5), which potentiate both presynaptic glutamate release and postsynaptic NMDA currents, and group II (mGluR2 and mGluR3) and Group III receptors (mGluR4, mGluR6, mGluR7, and mGluR8), which in general suppress glutamate function.(31,32) Glutamate re…”
Baldwin, D. S., Loft, H., & Dragheim, M. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.11.008 · Cited by 164
Pharmacological manipulation of mGlu2 receptors influences cognitive performance in the rodent
Higgins, G. A., Ballard, T. M., Kew, J. N. C., Richards, J. G., Kemp, J. A., Adam, G., Woltering, T. J., Nakanishi, S., & Mutel, V. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.01.018 · Cited by 162
Llado-Pelfort, L., Santana, N., Ghisi, V., Artigas, F., & Celada, P. (2012) · Cerebral Cortex · doi:10.1093/cercor/bhr220 · Cited by 156
Pehrson, A. L., Cremers, T., Bétry, C., van der Hart, M. G. C., Jørgensen, L., Madsen, M., Haddjeri, N., Ebert, B., & Sanchez, C. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.006 · Cited by 155
Self-citationAntidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model
Knapp, R. J., Goldenberg, R., Shuck, C., Cecil, A., Watkins, J. B., Miller, C., Crites, G. J., & Malatyńska, E. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01338-9 · Cited by 153
In Vivo Excitation of GABA Interneurons in the Medial Prefrontal Cortex through 5-HT3 Receptors
Puig, M. V. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh097 · Cited by 152
Henigsberg, N., Mahableshwarkar, A. R., Jacobsen, P., Chen, Y., & Thase, M. E. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07470 · Cited by 150
GABA and glutamate systems as therapeutic targets in depression and mood disorders
Kendell, S. F., Krystal, J. H., & Sanacora, G. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.1.153 · Cited by 150
Naismith, S. L., Longley, W. A., Scott, E. M., & Hickie, I. B. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-32 · Cited by 146
Mahableshwarkar, A. R., Jacobsen, P. L., & Chen, Y. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761600 · Cited by 135
Jain, R., Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Thase, M. E. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000727 · Cited by 132 · cited 1×
“Further, in clinical studies, its efficacy as an antidepressant has been demonstrated in several studies to date, although statistically significant separation from placebo has not been observed in every clinical trial.(146,147) Recently, it was reported that vortioxetine enhanced time-dependent contextual fear memory…”
Horiguchi, M., Huang, M., & Meltzer, H. Y. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180638 · Cited by 130
Martinez, D., Hwang, D., Mawlawi, O., Slifstein, M., Kent, J., Simpson, N., Parsey, R. V., Hashimoto, T., Huang, Y., Shinn, A., et al. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00187-1 · Cited by 130
Newman‐Tancredi, A., Martel, J., Assié, M., Buritova, J., Lauressergues, E., Cosi, C., Heusler, P., Bruins Slot, L., Colpaert, F., Vacher, B., et al. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00001.x · Cited by 128
Boulenger, J.-P., Loft, H., & Florea, I. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112441866 · Cited by 127
Meneses, A. (2004) · Behavioural Brain Research · doi:10.1016/j.bbr.2004.04.026 · Cited by 125
Redrobe, J. P., MacSweeney, C. P., & Bourin, M. (1996) · European Journal of Pharmacology · doi:10.1016/s0014-2999(96)00772-8 · Cited by 123
Heinrich, T., Böttcher, H., Gericke, R., Bartoszyk, G. D., Anzali, S., Seyfried, C. A., Greiner, H. E., & van Amsterdam, C. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040793q · Cited by 117
Differential modulation of Ih by 5‐HT receptors in mouse CA1 hippocampal neurons
Bickmeyer, U., Heine, M., Manzke, T., & Richter, D. W. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.02072.x · Cited by 116
AMPA Receptors in the Therapeutic Management of Depression
Bleakman, D., Alt, A., & Witkin, J. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707780363258 · Cited by 114
Zajaczkowski, W., Frankiewicz, T., Parsons, C. G., & Danysz, W. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(97)00070-1 · Cited by 112
Lamotrigine as Adjunct to Paroxetine in Acute Depression: A Placebo-Controlled, Double-Blind Study
Normann, C., Hummel, B., Scharer, L. O., Horn, M., Grunze, H., & Walden, J. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0411 · Cited by 107
Pindolol Augmentation of Antidepressant Response
Artigas, F., Adell, A., & Celada, P. (2006) · Current Drug Targets · doi:10.2174/138945006775515446 · Cited by 106
Obrocea, G. V., Dunn, R. M., Frye, M. A., Ketter, T. A., Luckenbaugh, D. A., Leverich, G. S., Speer, A. M., Osuch, E. A., Jajodia, K., & Post, R. M. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01206-9 · Cited by 105
Lladó‐Pelfort, L., Assié, M., Newman‐Tancredi, A., Artigas, F., & Celada, P. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00738.x · Cited by 103
Depoortère, R., Auclair, A. L., Bardin, L., Colpaert, F. C., Vacher, B., & Newman‐Tancredi, A. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.04.005 · Cited by 101
Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice
Kos, T., Popik, P., Pietraszek, M., Schäfer, D., Danysz, W., Драволина, О. А., Blokhina, E. A., Леонидович, Г. Т., & Bespalov, A. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.10.001 · Cited by 96
Francis, P. T., Poynton, A., Lowe, S. L., Najlerahim, A., Bridges, P. K., Bartlett, J. R., PROCTER, A. W., Bruton, C. J., & Bowen, D. M. (1989) · Brain Research · doi:10.1016/0006-8993(89)90600-8 · Cited by 96
Page, M. E., Cryan, J. F., Sullivan, A., Dalvi, A., Saucy, B., Manning, D. R., & Lucki, I. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034280 · Cited by 95
Tatarczy??ska, E., K??odzi??ska, A., Stachowicz, K., & Chojnacka-W??jcik, E. (2004) · Behavioural Pharmacology · doi:10.1097/00008877-200412000-00001 · Cited by 91
Horiguchi, M., & Meltzer, H. Y. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2561-4 · Cited by 91
Li, Y., Pehrson, A. L., Budac, D. P., Sánchez, C., & Gulinello, M. E. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.06.034 · Cited by 90
Self-citation5-HT7 receptors increase the excitability of rat hippocampal CA1 pyramidal neurons
Tokarski, K., Zahorodna, A., Bobula, B., & Hess, G. (2003) · Brain Research · doi:10.1016/j.brainres.2003.09.015 · Cited by 87
Boeijinga, P. H., & Boddeke, H. W. G. M. (1996) · Brain Research · doi:10.1016/0006-8993(96)00149-7 · Cited by 75
5-HT3 receptor antagonists reverse helpless behaviour in rats
Martin, P., GOZLAN, H., & Puech, A. J. (1992) · European Journal of Pharmacology · doi:10.1016/0014-2999(92)90074-e · Cited by 75
The effects of reboxetine on emotional processing in healthy volunteers: an fMRI study
Norbury, R., Mackay, C. E., Cowen, P. J., Goodwin, G. M., & Harmer, C. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002091 · Cited by 75
Spatial memory deficits following stimulation of hippocampal 5-HT1B receptors in the rat
Buhot, M.-C., Patra, S. K., & Naïli, S. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00407-c · Cited by 75
Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat
McLean, S. L., Woolley, M. L., Thomas, D. W., & Neill, J. C. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1618-0 · Cited by 74
Carr, D. B., & Sesack, S. R. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199807)29:3<193::aid-syn1>3.0.co;2-1 · Cited by 73
Riluzole Augmentation for Treatment-Resistant Depression
Sanacora, G., Kendell, S. F., Fenton, L. R., Coric, V., & Krystal, J. H. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.2132 · Cited by 72
Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
Baldwin, D. S., Hansen, T., & Florea, I. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.725035 · Cited by 71
5-HT3-like receptors in the rat medial prefrontal cortex: an electrophysiological study
Ashby, C. R., Minabe, Y., Edwards, E., & Wang, R. Y. (1991) · Brain Research · doi:10.1016/0006-8993(91)91316-s · Cited by 70
Bespalov, A., van Gaalen, M. M., Sukhotina, I. A., Wicke, K. M., Mezler, M., Schoemaker, H., & Groß, G. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.089 · Cited by 70
The Current Understanding of Lamotrigine as a Mood Stabilizer
Hahn, C.-G., Gyulai, L., Baldassano, C. F., & Lenox, R. H. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0610 · Cited by 63
Bétry, C., Pehrson, A. L., Etiévant, A., Ebert, B., Sánchez, C., & Haddjeri, N. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001058 · Cited by 62
Self-citation5-HT1AReceptors Modulate the Consolidation of Learning in Normal and Cognitively Impaired Rats
Meneses, A., & Hong, E. (1999) · Neurobiology of Learning and Memory · doi:10.1006/nlme.1998.3866 · Cited by 62
Ondansetron and arecoline prevent scopolamine-induced cognitive deficits in the marmoset
Carey, G. J., Costall, B., Domeney, A. M., Gerrard, P. A., Jones, D. N. C., Naylor, R. J., & Tyers, M. B. (1992) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(92)90449-p · Cited by 61
Fowler, S., Walker, J. M., Klakotskaia, D., Will, M. J., Serfözö, P. D., Simonyi, Á., & Schachtman, T. R. (2012) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2012.10.010 · Cited by 59
Ondansetron improves cognitive performance in the Morris water maze spatial navigation task
Fontana, D., Daniels, S. E., Henderson, C., Eglen, R. M., & Wong, E. H. F. (1995) · Psychopharmacology · doi:10.1007/bf02245812 · Cited by 58
Waters, K. A., Stean, T. O., Hammond, B., Virley, D. J., Upton, N., Kew, J. N. C., & Hussain, I. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.12.009 · Cited by 57
Glutamate-based depression GBD
McCarthy, D. J., Alexander, R., Smith, M. A., Pathak, S., Kanes, S., Lee, C., & Sanacora, G. (2012) · Medical Hypotheses · doi:10.1016/j.mehy.2012.02.009 · Cited by 54
5-HT7 receptors modulate GABAergic transmission in rat hippocampal CA1 area.
Tokarski, K., Kusek, M., & Hess, G. (2011) · PubMed · Cited by 53
Bonaventure, P., Aluisio, L., Shoblock, J., Boggs, J. D., Fraser, I. C., Lord, B., Lovenberg, T. W., & Galici, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020210 · Cited by 51
de Paulis, T. (2007) · PubMed · Cited by 49
The Pharmacology of the Neurochemical Transmission in the Midbrain Raphe Nuclei of the Rat
Harsing, L. (2006) · Current Neuropharmacology · doi:10.2174/157015906778520764 · Cited by 49
Beyond psychoanaleptics – can we improve antidepressant drug nomenclature?
Nutt, D. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109105498 · Cited by 48
Nikiforuk, A. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.09.006 · Cited by 47
Baldwin, D. S., Loft, H., & Florea, I. (2012) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283530ad7 · Cited by 47
Could the 5-HT1B receptor inverse agonism affect learning consolidation?
Meneses, A. (2001) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00007-0 · Cited by 46
Effects of 5-HT3 Receptor Antagonism on Hippocampal Cellular Activity in the Freely Moving Rat
Reznic, J., & Staubli, U. (1997) · Journal of Neurophysiology · doi:10.1152/jn.1997.77.1.517 · Cited by 46
Serotonin 5-HT1A Receptors Modulate Hippocampal Reactivity to Afferent Stimulation
Levkovitz, Y., & Segal, M. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-14-05591.1997 · Cited by 45
Tsuji, M., Takeda, H., & Matsumiya, T. (2002) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300080 · Cited by 45
Stahl, S. M. (2010) · CNS Spectrums · doi:10.1017/s1092852900027334 · Cited by 40 · cited 1×
“In recent years, antidepressant combination therapies with multifunctional pharmacologic mechanisms have been used to enhance therapeutic outcomes.(1) Some combinations include an SSRI plus the 5-HT1A receptor and b adrenergic receptor antagonist pindolol,(2) or SSRIs augmented with atypical antipsychotics.”
Smythies, J. (2005) · International review of neurobiology · doi:10.1016/s0074-7742(05)64005-6 · Cited by 39
Mlinar, B., Falsini, C., & Corradetti, R. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705026 · Cited by 38
Wang, S., Zhang, Q. J., Liu, J., Wu, Z., Ali, U., Wang, Y., Chen, L., & Gui, Z. H. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.04.069 · Cited by 38
A review of current evidence for vilazodone in major depressive disorder
Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2013) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2013.794245 · Cited by 37
The Serotonin-7 Receptor as a Novel Therapeutic Target
Stahl, S. M. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10bs06601gry · Cited by 35
Eriksson, T. M., Madjid, N., Elvander-Tottie, E., Stiedl, O., Svenningsson, P., & Ögren, S. O. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.02.007 · Cited by 34
Glutamate system as target for development of novel antidepressants
Catena-Dell’Osso, M., Fagiolini, A. M., Rotella, F., Baroni, S., & Marazziti, D. (2013) · CNS Spectrums · doi:10.1017/s1092852912000971 · Cited by 33
Herremans, A. H. J., Hijzen, T. H., Olivier, B., & Slangen, J. L. (1995) · Journal of Psychopharmacology · doi:10.1177/026988119500900307 · Cited by 32
Peddie, C. J., Davies, H. A., Colyer, F. M., Stewart, M. G., & Rodríguez, J. J. (2008) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2008.05.001 · Cited by 32
Fan, L., Zhang, Q. J., Liu, J.-R., Feng, J., Gui, Z. H., Ali, U., Zhang, L., Hou, C., Wang, T., Hui, Y. P., et al. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.06.011 · Cited by 32
Serotonin 1B receptor regulation after dorsal subiculum deafferentation
Amara, D. A., Ségu, L., Naïli, S., & Buhot, M.-C. (1995) · Brain Research Bulletin · doi:10.1016/0361-9230(95)00066-n · Cited by 29
Stępień, A., Chalimoniuk, M., & Strosznajder, J. B. (1999) · Cephalalgia · doi:10.1046/j.1468-2982.1999.1910859.x · Cited by 29
Liang, X., Arvanov, V. L., & Wang, R. Y. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199807)29:3<257::aid-syn8>3.0.co;2-5 · Cited by 27
Duncan, M. J., & Congleton, M. R. (2010) · Brain Research · doi:10.1016/j.brainres.2010.09.103 · Cited by 26
Pitsikas, N., & Borsini, F. (1996) · European Journal of Pharmacology · doi:10.1016/0014-2999(96)00586-9 · Cited by 24
Hamlyn, E., Brand, L., Shahid, M., & Harvey, B. H. (2009) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e328331ba1b · Cited by 23
Pangalos, M. N., Malizia, A. L., Francis, P. T., Lowe, S. L., Bertolucci, P. H. F., PROCTER, A. W., Bridges, P. K., Bartlett, J. R., & Bowen, D. M. (1992) · The British Journal of Psychiatry · doi:10.1192/bjp.160.5.638 · Cited by 22
Mahesh, R., Bhatt, S., Devadoss, T., Jindal, A. K., Gautam, B., & Pandey, D. K. (2012) · Journal of Young Pharmacists · doi:10.4103/0975-1483.104367 · Cited by 19
Koliaki, C. C., Messini, C., & Tsolaki, M. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00244.x · Cited by 18
Effects of ondansetron on short-term memory retrieval in mice.
Roychoudhury, M., & Kulkarni, S. K. (1997) · PubMed · Cited by 18
Peddie, C. J., Davies, H. A., Colyer, F. M., Stewart, M. G., & Rodríguez, J. J. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.09.024 · Cited by 16
d-Cycloserine enhances spatial memory in spontaneous place recognition in rats
Ozawa, T., Kumeji, M., Yamada, K., & Ichitani, Y. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.12.031 · Cited by 13
Guay, D. R. P. (2012) · The Consultant Pharmacist · doi:10.4140/tcp.n.2012.857 · Cited by 13
Pehrson, A. L., Nielsen, K. G. D. J., Jensen, J. B., & Sánchez, C. (2012) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(12)70405-4 · Cited by 8
Self-citationSanchez, C., Robichaud, P. J., Pehrson, A. L., & Leiser, S. C. (2012) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(12)70363-2 · Cited by 4
Self-citationSkelin, I., Kovačević, T., Sato, H., & Dikšić, M. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.04.009 · Cited by 3
Research works printed but not linked: 1
- Westrich L, Pehrson A, Zhong H, etal In vitro and in vivo effects of the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract. 2012; 5(suppl 1): 47– 47
Cited by
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547
McIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433
Mahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.52 · Cited by 307
Cognitive remission: a novel objective for the treatment of major depression?
Bortolato, B., Miskowiak, K. W., Köhler, C. A., Maes, M., Fernandes, B. S., Berk, M., & Carvalho, A. F. (2016) · BMC Medicine · doi:10.1186/s12916-016-0560-3 · Cited by 252
Pham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
Metadata
- Authors
- Pehrson, A. L., & Sanchez, C.
- Affiliations
- Lundbeck (United States) (US)
- ORCID
- Pehrson, Alan L.
- Venue
- CNS Spectrums
- Publisher
- Cambridge University Press (CUP)
- Published
- 2013-08-01
- Volume
- 19
- Issue
- 2
- Pages
- 121-133
- ISSN
- 1092-8529 (ISSN-L)
- 2165-6509
- PMC
- PMC3968911
- OpenAlex
- W2109860355
- Cited by
- 161
- References
- 153
- Citations by year
- 2026: 7 · 2025: 6 · 2024: 10 · 2023: 10 · 2022: 8 · 2021: 9 · 2020: 5 · 2019: 19 · 2018: 9 · 2017: 21 · 2016: 15 · 2015: 25 · 2014: 13 · 2013: 4
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- CNS Spectrums (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- serotonergic modulation, glutamatergic neurotransmission, depression, cognitive impairment, 5-HT1A receptor, 5-HT1B receptor, 5-HT3 receptor, 5-HT7 receptor, vortioxetine, vilazodone, ketamine, antidepressant efficacy, multimodal antidepressant
- MeSH terms
- Animals, Cognition Disorders, Depression, Humans, Synaptic Transmission, Serotonin, Serotonin Agents, Glutamic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.